Combined haptoglobin and hemopexin therapy for the treatment of cardiopulmonary dysfunction in sickle cell disease.

Saved in:
Bibliographic Details
Title: Combined haptoglobin and hemopexin therapy for the treatment of cardiopulmonary dysfunction in sickle cell disease.
Authors: Lucero MJ; University of Colorado, Anschutz Medical Campus School of Medicine, Translational Research Laboratory of Red Blood Cell Diseases and Hypoxia Related Illnesses, Cardiovascular Pulmonary Research (CVP) Program, Pediatrics, USA., Lisk C; University of Colorado, Anschutz Medical Campus School of Medicine, Translational Research Laboratory of Red Blood Cell Diseases and Hypoxia Related Illnesses, Cardiovascular Pulmonary Research (CVP) Program, Pediatrics, USA., Swindle D; University of Colorado, Anschutz Medical Campus School of Medicine, Translational Research Laboratory of Red Blood Cell Diseases and Hypoxia Related Illnesses, Cardiovascular Pulmonary Research (CVP) Program, Pediatrics, USA., Cendali F; Department of Biochemistry and Molecular Genetics, University of Colorado, Anschutz Medical Campus, USA., Setua S; University of Maryland, School of Medicine, Center for Blood Oxygen Transport and Hemostasis, Department of Pediatrics, Baltimore, MD, USA., Thangaraju K; University of Maryland, School of Medicine, Center for Blood Oxygen Transport and Hemostasis, Department of Pediatrics, Baltimore, MD, USA., Khan A; University of Maryland, School of Medicine, Center for Blood Oxygen Transport and Hemostasis, Department of Pediatrics, Baltimore, MD, USA., Pak DI; University of Colorado, Anschutz Medical Campus School of Medicine, Translational Research Laboratory of Red Blood Cell Diseases and Hypoxia Related Illnesses, Cardiovascular Pulmonary Research (CVP) Program, Pediatrics, USA., O'Boyle Q; William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH 43210, USA., Lu S; William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH 43210, USA., Tolson R; University of Colorado, Anschutz Medical Campus School of Medicine, Translational Research Laboratory of Red Blood Cell Diseases and Hypoxia Related Illnesses, Cardiovascular Pulmonary Research (CVP) Program, Pediatrics, USA., Zaeske S; University of Colorado, Anschutz Medical Campus School of Medicine, Translational Research Laboratory of Red Blood Cell Diseases and Hypoxia Related Illnesses, Cardiovascular Pulmonary Research (CVP) Program, Pediatrics, USA., Khan S; University of Colorado, Anschutz Medical Campus School of Medicine, Translational Research Laboratory of Red Blood Cell Diseases and Hypoxia Related Illnesses, Cardiovascular Pulmonary Research (CVP) Program, Pediatrics, USA., Rana N; University of Colorado, Anschutz Medical Campus School of Medicine, Translational Research Laboratory of Red Blood Cell Diseases and Hypoxia Related Illnesses, Cardiovascular Pulmonary Research (CVP) Program, Pediatrics, USA., Westover N; University of Colorado, Anschutz Medical Campus School of Medicine, Translational Research Laboratory of Red Blood Cell Diseases and Hypoxia Related Illnesses, Cardiovascular Pulmonary Research (CVP) Program, Pediatrics, USA., Davizon-Castillio P; Bloodworks Northwest University of Washington, Seattle Children's Hospital, USA., George G; Bloodworks Northwest University of Washington, Seattle Children's Hospital, USA; Division of Hematology Colorado Sickle Cell Treatment and Research Center, School of Medicine, Anschutz Medical Campus, University of Colorado, Denver School of Medicine, Aurora, CO, USA., Hassell K; Bloodworks Northwest University of Washington, Seattle Children's Hospital, USA; Division of Hematology Colorado Sickle Cell Treatment and Research Center, School of Medicine, Anschutz Medical Campus, University of Colorado, Denver School of Medicine, Aurora, CO, USA., Nuss R; Bloodworks Northwest University of Washington, Seattle Children's Hospital, USA; Division of Hematology Colorado Sickle Cell Treatment and Research Center, School of Medicine, Anschutz Medical Campus, University of Colorado, Denver School of Medicine, Aurora, CO, USA., Brinkman N; CSL Behring LLC., Plasma Protein Research & Development, Kankakee, IL, USA., Gentinetta T; CSL, CSL Biologics Research Center, Bern, Switzerland; Swiss Institute for Translational and Entrepreneurial Medicine, sitem-insel, Bern, Switzerland., Niemeyer C; University of Colorado, Anschutz Medical Campus School of Medicine, Department of Neurology, Aurora, CO, USA., Cabrales P; Department of Bioengineering, University of California San Diego, San Diego, CA, USA., Palmer A; William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH 43210, USA., D'Alessandro A; Department of Biochemistry and Molecular Genetics, University of Colorado, Anschutz Medical Campus, USA., Buehler PW; University of Maryland, School of Medicine, Center for Blood Oxygen Transport and Hemostasis, Department of Pediatrics, Baltimore, MD, USA. Electronic address: pbuehler@som.umaryland.edu., Irwin DC; University of Colorado, Anschutz Medical Campus School of Medicine, Translational Research Laboratory of Red Blood Cell Diseases and Hypoxia Related Illnesses, Cardiovascular Pulmonary Research (CVP) Program, Pediatrics, USA. Electronic address: david.irwin@cuanschutz.edu.
Source: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2025 Nov; Vol. 192, pp. 118595. Date of Electronic Publication: 2025 Sep 24.
Publication Type: Journal Article
Journal Info: Publisher: Editions Scientifiques Elsevier Country of Publication: France NLM ID: 8213295 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1950-6007 (Electronic) Linking ISSN: 07533322 NLM ISO Abbreviation: Biomed Pharmacother Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1950-6007
DOI:10.1016/j.biopha.2025.118595